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Aims: To investigate the effect on risk of major adverse cardiac events (MACE) of lipid lowering treatment
with fluvastatin 80 mg/day after a first percutaneous coronary intervention in patients with stable and
unstable angina.
Method and results: This prespecified subgroup analysis of the LIPS (Lescol intervention prevention study)
analysed 1658 patients with documented diagnosis; 824 had unstable angina (417 randomly assigned to
fluvastatin, 407 to placebo) and 834 had stable angina (including silent ischaemia; fluvastatin, 418;
placebo, 416). Median follow up was 3.9 years. There was no significant effect of anginal status on long
term risk of MACE. Fluvastatin treatment reduced the risk of MACE by 28% compared with placebo
(p = 0.03) among patients with unstable angina, with no difference between patients with stable and
patients with unstable angina (relative risk 1.07, 95% confidence interval 0.87 to 1.30, p = 0.53).
Fluvastatin reduced coronary atherosclerotic events (MACE excluding restenosis) by 36% (p = 0.006)
among patients with unstable angina and 31% (p = 0.02) among patients with stable angina. Fluvastatin
caused similar reductions in total cholesterol and low density lipoprotein cholesterol concentrations in both
patient groups.
Conclusion: Treatment with fluvastatin 80 mg/day produced significant reductions in MACE and coronary
atherosclerotic events after percutaneous coronary intervention in patients with average cholesterol
concentrations. The beneficial effects of fluvastatin are observed in patients with unstable or stable angina
alike.
R
ecent evidence suggests that coronary artery disease is a
systemic disorder.1 2 Although percutaneous coronary
intervention (PCI) effectively improves symptoms by
restoring coronary perfusion, the underlying systemic inflam-
matory and prothrombotic substrates are not attenuated and
so life long medication is necessary after revascularisation. In
particular, lipid lowering treatment with 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors (statins)
has been proved to improve survival in patients with coronary
artery disease.3–6 The underlying mechanisms for the bene-
ficial effects of statins in patients with coronary artery disease
are not fully understood but are likely to involve reductions
in lipid concentrations, improvement in endothelial func-
tion,7 8 anti-inflammatory action,9–12 or antithrombotic
actions,11–13 or a combination of these effects.14 15
The recent LIPS (Lescol intervention prevention study)
showed that early initiation of lipid lowering treatment with
fluvastatin at hospital discharge significantly reduces the
incidence of major adverse cardiac events (MACE) among
patients after PCI with average cholesterol concentrations.16
Fluvastatin treatment was well tolerated and associated with
no significant side effects. In the present study, patients were
classified at entry as having either unstable angina or stable
angina, conditions that exhibit major differences in patho-
physiology,17–19 prognosis,20 and response to treatment.21 In
contrast to stable angina, which is caused by a fixed stenotic
coronary lesion that impairs myocardial perfusion, unstable
angina is usually caused by the rupture or erosion of an
atherosclerotic plaque, leading to a reaction cascade that
results in a thrombotic milieu.22 23 There is relatively little
information regarding the effect of statin treatment in
patients with unstable angina; hence, this study provides
important insight into the potential benefits of statins in this
patient group.
The objective of the present study was thus to investigate
the effects of fluvastatin on the incidence of long term
adverse events among patients with unstable angina or stable
angina enrolled in LIPS.
METHODS
Patients
Patients were recruited into LIPS from 57 centres in 10
countries between April 1996 and October 1998. The study
population was composed of 1677 patients (1406 men and
271 women, age 18–80 years). All patients had successfully
undergone a first PCI (index procedure) in the native
coronary arteries. Patients qualifying for enrolment in LIPS
had diagnosed unstable angina (according to the Braunwald
classification), stable angina (according to the Canadian
Cardiovascular Society classification), or silent ischaemia.
Patients were eligible for enrolment in the study if they
had a total cholesterol concentration of 3.5–7.0 mmol/l (135–
270 mg/dl) with fasting triglyceride concentrations of less
than 4.5 mmol/l (400 mg/dl) before the index procedure.
Abbreviations: CI, confidence interval; LIPS, Lescol intervention
prevention study; MACE, major adverse cardiac events; PCI,
percutaneous coronary intervention; RR, relative risk
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Exclusion criteria were sustained systolic blood pressure
. 180 mm Hg and diastolic blood pressure . 100 mm Hg
despite drug treatment; left ventricular ejection fraction
, 30%; a history of previous PCI or CABG, severe valvar
disease, idiopathic cardiomyopathy, or congenital heart
disease; severe renal dysfunction (defined as serum creati-
nine concentration . 160 mmol/l (1.8 mg/dl)); obesity
(defined as a body mass index . 35 kg/m2); or the presence
of malignant or other disease with a life expectancy of less
than four years.
All patients provided informed written consent and the
ethics committee at each participating centre approved the
trial.
Study design
After inclusion, patients were randomly assigned to receive
either fluvastatin 40 mg twice daily (Lescol, Novartis Pharma
AG, Basel, Switzerland) or matching placebo for a period of at
least three years and no longer than four years. The study
design of LIPS has been described in more detail elsewhere.24
End points
The primary end point was MACE, defined as cardiac death,
non-fatal myocardial infarction, or repeat intervention
procedure. Prespecified secondary end points were MACE
excluding repeat intervention procedures occurring in the
first six months for lesions treated at the index procedure
(MACE without restenosis or coronary atherosclerotic
events) and cardiac death/non-fatal myocardial infarction.
Secondary end points also included treatment effects on
measured lipid concentrations throughout the trial, as well as
the safety and tolerability of fluvastatin. Details and results of
the main trial have been provided elsewhere.16
Laboratory measures, including serum total cholesterol,
low density lipoprotein cholesterol, high density lipoprotein
cholesterol, and fasting triglyceride concentrations, were
determined from fasting blood samples and assessed
at a central laboratory (Analytico Medinet, Breda, the
Netherlands). Laboratory values were measured at baseline,
at a clinical visit six weeks after discharge, and at six month
intervals thereafter until the conclusion of the study. Study
personnel and patients were not informed of the lipid results.
Statistical analysis
All analyses were carried out on an intention to treat basis.
Continuous variables are expressed as mean (SD) and were
compared by Student’s unpaired t test. Wilcoxon scores were
used for categorical variables with an ordinal scale. Discrete
variables are expressed as counts and percentages and were
compared in terms of relative risks (RR) (for unstable angina
compared with stable angina) with 95% confidence interval
(CI). All statistical tests were two tailed. Event-free survival
distribution was estimated according to the Kaplan-Meier
method. MACE-free survival time was tested with the log
rank test. Patients lost to follow up were considered at risk
until the date of last contact, at which point they were
censored. The Cox proportional hazards model and the
Cochran-Mantel-Haenszel test were used to assess risk
reduction and to compare the incidences of the primary
and secondary clinical end points, respectively. The treatment
by anginal status interaction was calculated in a multivariate
approach with treatment, anginal stability, and an interac-
tion factor specifying the simultaneous presence or absence
of both previous factors in the model. This enabled us to
calculate the fluvastatin effect in patients with stable angina
separate from the same effect in patients with unstable
angina, as well as to calculate the anginal status effect in the
patients given placebo and those given fluvastatin.
The lipid profiles were analysed in an analysis of
covariance model incorporating the baseline (at visit 1) as
covariate, adding the factors treatment, visit number (visits
. 1), and subgroup with all possible interaction terms.
RESULTS
Patient characteristics
Of the 1677 patients enrolled in LIPS, data regarding
qualifying diagnosis were complete for 1658 (98.9%) patients.
These patients were classed as having either unstable
angina (total, 824; fluvastatin, 417; placebo, 407) or stable
angina (total, 834; fluvastatin, 418; placebo, 416). Patients
with silent ischaemia were included in the stable angina
group.
Table 1 shows baseline characteristics (demographic and
angiographic). There were no notable differences in the
baseline and procedural characteristics between the groups.
The left anterior descending artery was the affected vessel in
a larger proportion of patients with unstable angina than
in the stable angina group. The unstable angina group also
had a higher incidence of American Heart Association
classification type B2 lesions and stent implantation. In
contrast, patients with diagnosed stable angina had a
higher incidence of American Heart Association classifi-
cation type C lesions and balloon angioplasty. In the
unstable angina group, patients randomly assigned to
fluvastatin had a higher incidence of diabetes mellitus and
a lower incidence of previous stroke than did patients
randomly assigned to placebo. Overall, patients randomly
assigned to fluvastatin or placebo in the stable angina group
were well matched.
The median time between index PCI and randomisation
was two days in both groups (range 0–22 days in the unstable
angina group and 0–21 days in the stable angina group). The
median time from index PCI to initiation of study medication
was also two days. The median follow up was 3.9 years in
both groups.
Up to the time of the first MACE or completion of follow
up among patients without MACE, 17.6% (unstable
angina group) and 17.5% (stable angina group) of patients
were taking the study treatment regimen less than 80%
of the time and were not taking other lipid lowering drugs.
It is worth noting that 16.9% of patients in the unstable
angina group and 17.6% of patients in the stable angina
group were taking other lipid lowering drugs (generally other
statins).
The proportion of patients taking other cardiovascular
drugs during the course of the study was similar between the
groups. Concurrent treatments included aspirin, b blockers,
calcium antagonists, nitrates, angiotensin converting enzyme
inhibitors, and diuretics.
Long term risk of unstable versus stable angina after
PCI
Among patients randomly assigned to placebo, the overall
incidence of MACE was similar in patients with unstable
angina (27.3%) and patients with stable angina (26.2%) (RR
0.88, 95% CI 0.66 to 1.17, p = 0.37). The overall incidence of
MACE in the two angina categories was also similar in
patients randomly assigned to receive fluvastatin (unstable
versus stable angina 20.9% v 22.3%, RR 1.0, 95% CI 0.73 to
1.37, p = 1.0). Overall, there was no significant effect of
anginal status on long term risk of MACE (RR 0.94, 95% CI
0.75 to 1.17, p = 0.56). Similarly, there was no significant
difference in risk between patients with unstable angina and
those with stable angina in other end points, including
cardiac death/non-fatal MI or coronary atherosclerotic events
(MACE without restenosis).
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Effect of fluvastatin in unstable and stable angina
after PCI
Table 2 shows the effect of fluvastatin on the time to first end
point. In patients with unstable angina, fluvastatin treatment
produced a significant risk reduction for MACE of 28%
(p = 0.03). The treatment-status interaction analysis
showed that the effect of fluvastatin treatment did not differ
significantly between patients with stable angina and
patients with unstable angina (RR 1.07, 95% CI 0.87 to
1.30, p = 0.53). The Kaplan-Meier curves for fluvastatin and
placebo groups started to separate at around 1.5 years and the
benefits of fluvastatin treatment appeared to increase with
time (fig 1).
Table 2 shows the effects of fluvastatin on other
prespecified cardiovascular outcomes and fig 1 compares
these outcomes. In patients with unstable angina, fluvastatin
treatment significantly lowered the risk of coronary athero-
sclerotic events (incidence 23.1% with placebo v 16.3%,
RR = 0.64, 95% CI 0.46 to 0.88; p = 0.006) but not the risk
of cardiac death/non-fatal myocardial infarction (incidence
Table 1 Patient demographics and characteristics at baseline
Unstable angina Stable angina
Fluvastatin
(n = 417)
Placebo
(n = 407)
Fluvastatin
(n = 418)
Placebo
(n = 416)
Age (years) 60.7 (10.2) 60.2 (9.9) 59.5 (10.0) 59.8 (9.8)
Men 344 (82.5%) 336 (82.6%) 360 (86.1%) 350 (84.1%)
BMI (kg/m2) 26.9 26.3 26.5 26.5
Risk factors
Smoking (previous and current) 303 (72.7%) 297 (73.0%) 293 (70.1%) 288 (69.2%)
Diabetes 65 (15.6%) 34 (8.4%) 55 (13.2%) 48 (11.5%)
Hypertension 157 (37.6%) 158 (38.8%) 169 (40.4%) 157 (37.7%)
Family history of IHD 113 (27.4%) 119 (29.3%) 125 (30.0%) 131 (31.7%)
Previous MI 184 (44.1%) 172 (42.3%) 179 (42.8%) 192 (46.2%)
Previous stroke 10 (2.4%) 21 (5.2%) 7 (1.7%) 6 (1.4%)
Multivessel disease 148 (35.5%) 138 (339%) 170 (40.7%) 149 (35.8%)
Braunwald classification
IB 53 (12.7%) 49 (12.0%) NA NA
IIB 186 (44.6%) 195 (47.9%) NA NA
IIIB 82 (19.7%) 79 (19.4%) NA NA
IC 11 (2.6%) 10 (2.5%) NA NA
IIC 49 (11.8%) 34 (8.4%) NA NA
IIIC 36 (8.6%) 40 (9.8%) NA NA
CCS classification (%)
I NA NA 44 (10.5%) 45 (10.8%)
II NA NA 180 (43.1%) 161 (38.7%)
III NA NA 99 (23.7%) 101 (24.3%)
IV NA NA 23 (5.5%) 18 (4.3%)
Silent ischaemia NA NA 72 (17.2%) 91 (21.9%)
Baseline lipid concentration (mmol/)
Total cholesterol 5.17 (0.81) 5.16 (0.84) 5.19 (0.80) 5.17 (0.87)
LDL cholesterol 3.43 (0.75) 3.42 (0.79) 3.40 (0.76) 3.42 (0.80)
HDL cholesterol 0.95 (0.28) 0.95 (0.26) 1.00 (0.34) 0.98 (0.33)
Triglycerides 1.75 (0.68) 1.75 (0.71) 1.75 (0.87) 1.71 (0.73)
Systolic BP (mm Hg) 128 127 129 130
Diastolic BP (mm Hg) 74 75 76 76
Ejection fraction (%) 62.0 62.9 62.7 60.8
Lesion type (AHA class)
A 20.3% 18.6% 19.4% 20.1%
B1 34.1% 35.6% 35.3% 35.9%
B2 36.5% 36.2% 30.5% 29.6%
C 9.1% 9.6% 14.8% 14.4%
Type of PCI*
Balloon only 37.6% 38.7% 46.0% 44.8%
Stent 61.7% 58.8% 50.9% 52.3%
Others 3.4% 4.5% 4.4% 5.1%
*Percutaneous coronary intervention (PCI) categories are not mutually exclusive; hence, percentage values may not
total 100%.
AHA, American Heart Association; BMI, body mass index; BP, blood pressure; CCS, Canadian Cardiovascular
Society; HDL, high density lipoprotein; IHD, ischaemic heart disease; LDL, low density lipoprotein; MI, myocardial
infarction; NA, not applicable.
Table 2 Effects of fluvastatin on prespecified cardiovascular end points
End point
Unstable angina Stable angina
Fluvastatin
(n = 417)
Placebo
(n = 407) RR (95% CI) p Value
Fluvastatin
(n = 418)
Placebo
(n = 416) RR (95% CI) p Value
MACE without
restenosis
68 (16.3%) 94 (23.1%) 0.64 (0.46 to 0.88) 0.006 66 (15.8%) 92 (22.1%) 0.69 (0.50 to 0.95) 0.02
Cardiac death/non-
fatal MI
22 (5.3%) 35 (8.6%) 0.60 (0.34 to 1.03) 0.06 20 (4.8%) 24 (5.8%) 0.85 (0.46 to 1.55) 0.59
Time to first MACE NA NA 0.72 (0.47 to 0.90) 0.03 NA NA 0.80 (0.60 to 1.07) 0.13
NA, not applicable.
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8.6% with placebo v 5.3%, RR = 0.60, 95% CI 0.34 to 1.05;
p = 0.06). Fluvastatin also significantly decreased the risk of
coronary atherosclerotic events in patients with stable angina
(incidence 22.1% with placebo v 15.8%, RR = 0.69, 95% CI
0.50 to 0.95; p = 0.02), although the reduction in cardiac
death/non-fatal myocardial infarction was not significant
(incidence 5.8% with placebo v 4.8%, RR = 0.85, 95% CI 0.46
to 1.55; p = 0.59).
The proportion of patients with unstable angina with no
MACE did not vary significantly according to Braunwald
classification in either the fluvastatin (class I, 75%; class II,
80%; class III, 80%) or the placebo group (class I, 81%; class
II, 73%; class III, 68%).
Changes in lipid concentrations
Baseline lipid concentrations were similar in the unstable
angina and stable angina groups, as well as in the fluvastatin
and placebo arms within each group (table 1). Figure 2 and
table 3 show the changes in lipid concentrations with
fluvastatin analysed on an intention to treat basis.
Fluvastatin produced a significant reduction in total and
low density lipoprotein cholesterol concentrations in both the
unstable and stable angina groups, with comparable efficacy
in the two groups. Reductions in lipid concentrations were
first observed at visit 2 (six weeks after discharge) and were
maintained throughout the study period. Although high
density lipoprotein cholesterol concentrations increased
above baseline concentrations in both the unstable and
stable angina groups, similar increases were observed in
patients randomly assigned to placebo; hence, there was no
net benefit in favour of fluvastatin. Similarly, no significant
changes in triglyceride concentrations attributable to fluvas-
tatin were observed in either group.
Safety and tolerability
Full safety data have been reported previously.16 No
significant adverse events were observed with fluvastatin.
DISCUSSION
LIPS was the first prospective study of patients with average
lipid concentrations after successful PCI, with a significant
reduction of 22% in fatal or non-fatal MACE as a result of
early statin treatment with fluvastatin 80 mg/day. These
results support the use of early lipid lowering treatment with
fluvastatin for patients after PCI regardless of baseline lipid
concentration.
Most previous studies investigating the long term effects of
statin have focused on patients after an infarction or with
stable angina.3–6 Information regarding the effects of statin in
patients with unstable angina, particularly after PCI, is
scarce. LIPS therefore offered the opportunity to investigate
the effect of fluvastatin in patients with unstable angina who
had successfully undergone PCI, a group that made up
approximately half of the LIPS population.
The results of the present study show that patients classed
as having both unstable and stable angina in LIPS had an
Figure 1 Kaplan-Meier curves showing survival time free of adverse
coronary atherosclerotic events (cardiac death, non-fatal myocardial
infarction, and all reinterventions not caused by coronary restenosis) in
patients with stable or unstable angina randomly assigned to receive
either fluvastatin 80 mg/day or placebo.
Figure 2 Mean change in lipid concentrations throughout follow up
among patients with stable or unstable angina randomly assigned to
receive either fluvastatin 80 mg/day or placebo. (A) Total cholesterol;
(B) low density lipoprotein (LDL) cholesterol; (C) high density lipoprotein
(HDL) cholesterol; (D) triglyceride concentrations.
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impaired long term prognosis, with up to one quarter to one
third of patients experiencing one or more MACE within four
years of PCI. These findings emphasise the importance of
additional treatment after successful revascularisation.
Importantly, fluvastatin treatment was of clear benefit both
for patients with stable angina and for patients with unstable
angina and was associated with clinically relevant reductions
in the incidence of coronary atherosclerotic events in both
patient groups. The benefits of fluvastatin treatment in
reducing the incidence of MACE and prolonging the time to
first MACE were significant in patients with unstable angina.
A treatment-status interaction analysis showed no significant
difference in the effects of fluvastatin between patients with
unstable angina and patients with stable angina.
There was also no significant difference in outcome
between patients with stable angina and those with unstable
angina in the placebo group. This is somewhat surprising but
may be a result of the successful PCI that took place before
randomisation, which not only treats the obstructive lesion
but also stabilises any initially unstable culprit plaque.
Previous studies have shown that, after successful coronary
angioplasty, patients with unstable angina have a higher
event rate than do patients with stable angina. This has
generally been attributed to a higher repeat revascularisation
rate.21 In contrast, LIPS showed that unstable and stable
angina had comparable long term outcomes after successful
revascularisation. There are several possible reasons for the
difference. Firstly, this difference may reflect the more
widespread use of coronary stent, a technique that has been
proved to reduce restenosis25 in LIPS. Secondly, the inherited
bias of recruiting solely patients with unstable angina who
have undergone successful angioplasty could have effaced
the risk imposed by the disease entity. Thirdly, the admin-
istration of new adjunctive medications such as glycoprotein
IIb/IIIa inhibitors for unstable angina may also have
contributed to lowering the risk of this patient group.
For patients with unstable coronary syndrome, early
initiation of statin before hospital discharge has been
independently associated with a reduction in MACE in the
short term,26–28 as well as over long term follow up.29 However,
successful revascularisation was not an inclusion criterion in
these studies. It has also been reported that early initiation of
statin for patients with unstable angina undergoing stent
implantation is associated with an improvement in six month
outcomes.30 Long term event rates, however, were not
reported. Given the positive effects of fluvastatin on long
term outcomes in both patients with unstable angina and
those with stable angina in our analysis, extrapolation of
previous findings to all patients with coronary artery disease
who have undergone a first successful PCI seems reasonable.
The beneficial effects of statin among patients with
unstable angina may be attributed to its effect on vulnerable
plaques, as vulnerable plaque rupture is the major triggering
event for unstable coronary disease. Experimental data
suggest that statin, in addition to its lipid lowering effects,
may stabilise vulnerable plaques by converting lipid rich
plaques (which are at high risk of rupture) into more stable
fibrotic plaques.31
Study limitations
Because the number of patients with silent ischaemia was
small, this group was included in the stable angina group for
analysis. Patients with previous PCI or coronary bypass
surgery were excluded; hence, the conclusions of the present
study cannot be extrapolated to these patients. As this study
is an analysis of a subgroup, albeit prespecified, it suffers
from inherent limitations, such as the lack of sufficient
power, because of the limited number of patients in each
subgroup.
Conclusions
The results of the present study provide evidence for the long
term benefits of fluvastatin treatment initiated at hospital
discharge for all patients with angina after successful PCI. It
is worth noting that evidence from previous studies has
shown that early initiation of lipid lowering treatment before
hospital discharge also improves compliance.32 On the basis
of these findings, we suggest that early lipid lowering
treatment should be initiated for all patients after PCI,
regardless of baseline lipid concentrations and clinical
presentation.
ACKNOWLEDGEMENTS
This study was supported by a grant from Novartis Pharma AG.
Novartis provided the fluvastatin and matched placebo used in the
present study.
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
C H Lee, P de Feyter, P W Serruys, F Saia, P A Lemos, Erasmus Medical
Centre, Thoraxcentre, Rotterdam, the Netherlands
D Goedhart, Cardialysis BV, Rotterdam, the Netherlands
P R Soares, Heart Institute (InCor) of Sao Paulo University Medical
School, Sao Paulo, Brazil
V A W M Umans, Medical Centre Alkmaar, the Netherlands
M Ciccone, Dipartimento di Metodologia Clinica e Tecnologie Medico-
Chirurgiche, University of Bari, Bari, Italy
M Cortellaro, Istituto Policlinico S Donato, San Donato Milanese, Italy
REFERENCES
1 Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc Dis
2002;13(suppl 1):1–6.
2 Falk E. Multiple culprits in acute coronary syndromes: systemic disease calling
for systemic treatment. Ital Heart J 2000;1:835–8.
3 Sacks FM, Pfeffer MA, Moye LA, for the Cholesterol and Recurrent Events Trial
Investigators, et al. The effect of pravastatin on coronary events after
myocardial infarction in patients with average cholesterol levels. N Engl J Med
1996;335:1001–9.
4 Anon. Prevention of cardiovascular events and death with pravastatin in
patients with coronary heart disease and a broad range of initial cholesterol
levels. The long-term intervention with pravastatin in ischaemic disease (LIPID)
study group. N Engl J Med 1998;339:1349–57.
5 Anon. Long-term effectiveness and safety of pravastatin in 9014 patients with
coronary heart disease and average cholesterol concentrations: the LIPID trial
Table 3 Differences in blood lipid concentrations between fluvastatin and placebo treatment groups at the end of the study
Unstable angina Stable angina
Fluvastatin (n = 417) Placebo (n = 407) Fluvastatin (n = 418) Placebo (n = 416)
Concentration
(mmol/)
Change from
baseline
Concentration
(mmol/l)
Change from
baseline
Concentration
(mmol/l)
Change from
baseline
Concentration
(mmol/l)
Change from
baseline
Total cholesterol 20.65 212.6% 0.10 1.9% 20.62 211.9% 0.03 0.6%
LDL cholesterol 20.79 223.0% 20.04 21.2% 20.76 222.4% 20.09 22.6%
HDL cholesterol 0.21 22.1% 0.22 23.2% 0.17 17.0% 0.21 21.4%
Triglycerides 20.15 28.6% 20.15 28.6% 20.11 26.3% 20.17 29.9%
1160 Lee, de Feyter, Serruys, et al
www.heartjnl.com
 on 10 October 2006 heart.bmjjournals.comDownloaded from 
follow-up. The LIPID study group (long-term intervention with pravastatin in
ischaemic disease). Lancet 2002;359:1379–87.
6 Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular
events, and total mortality in the heart and estrogen/progestin replacement
study (HERS). HERS study group. Circulation 2002;105:2962–7.
7 Dupuis J, Tardif JC, Cernacek P, et al. Cholesterol reduction rapidly improves
endothelial function after acute coronary syndromes. The RECIFE (reduction of
cholesterol in ischemia and function of the endothelium) trial. Circulation
1999;99:3227–33.
8 Masumoto A, Hirooka Y, Hironaga K, et al. Effect of pravastatin on
endothelial function in patients with coronary artery disease (cholesterol-
independent effect of pravastatin). Am J Cardiol 2001;88:1291–4.
9 Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on
plasma concentration of C-reactive protein. The cholesterol and recurrent
events (CARE) investigators. Circulation 1999;100:230–5.
10 Martinez-Gonzalez J, Alfon J, Berrozpe M, et al. HMG-CoA reductase
inhibitors reduce vascular monocyte chemotactic protein-1 expression in early
lesions from hypercholesterolemic swine independently of their effect on
plasma cholesterol levels. Atherosclerosis 2001;159:27–33.
11 Ni W, Egashira K, Kataoka C, et al. Antiinflammatory and antiarteriosclerotic
actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition
of nitric oxide synthesis. Circ Res 2001;89:415–21.
12 Undas A, Brozek J, Musial J. Anti-inflammatory and antithrombotic effects of
statins in the management of coronary artery disease. Clin Lab
2002;48:287–96.
13 Lacoste L, Lam JY, Hung J, et al. Hyperlipidemia and coronary disease:
correction of the increased thrombogenic potential with cholesterol reduction.
Circulation 1995;92:3172–7.
14 Rauch U, Osende JI, Chesebro JH, et al. Statins and cardiovascular diseases:
the multiple effects of lipid-lowering therapy by statins. Atherosclerosis
2000;153:181–9.
15 Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation,
and plaque stability. Cardiovasc Res 2000;47:648–57.
16 Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of
cardiac events following successful first percutaneous coronary intervention: a
randomized controlled trial. Lescol intervention prevention study (LIPS)
investigators. JAMA 2002;287:3215–22.
17 Sullivan E, Kearney M, Isner JM, et al. Pathology of unstable angina: analysis
of biopsies obtained by directional coronary atherectomy. J Thromb
Thrombolysis 1994;1:63–71.
18 Walczak E, Krus S, Fiejka E, et al. Light and electron microscopic picture of
atherosclerotic plaque in stable and unstable angina. Pol J Pathol
1999;50:87–92.
19 Hoffmeister HM, Ehlers R, Buttcher E, et al. Comparison of C-reactive protein
and terminal complement complex in patients with unstable angina pectoris
versus stable angina pectoris. Am J Cardiol 2002;89:909–12.
20 Fiotti N, Di Chiara A, Altamura N, et al. Coagulation indicators in
chronic stable effort angina and unstable angina: relationship with acute
phase reactants and clinical outcome. Blood Coagul Fibrinolysis
2002;13:247–55.
21 Przewlocki T, Pieniazek P, Tracz W, et al. Long-term outcome in patients with
unstable angina treated by coronary balloon angioplasty. Int J Cardiol
2001;77:13–24.
22 Davies MJ, Thomas AC, Knapman PA, et al. Intramyocardial platelet
aggregation in patients with unstable angina suffering sudden ischemic
cardiac death. Circulation 1986;73:418–27.
23 Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis
leading to infarction and/or sudden death: autopsy evidence of recurrent
mural thrombosis with peripheral embolization culminating in total vascular
occlusion. Circulation 1985;71:699–708.
24 Serruys PW, De Feyter PJ, Benghozi R, et al. Lescol(R) intervention prevention
study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-
term effects of fluvastatin after successful transcatheter therapy in patients with
coronary heart disease. Int J Cardiovasc Intervent 2001;4:165–72.
25 Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-
expandable-stent implantation with balloon angioplasty in patients with
coronary artery disease. Benestent study group. N Engl J Med
1994;331:489–95.
26 Bybee KA, Wright RS, Williams BA, et al. Effect of concomitant or very early
statin administration on in-hospital mortality and reinfarction in patients with
acute myocardial infarction. Am J Cardiol 2001;87:771–4, A7.
27 Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early
mortality after acute coronary syndromes: an observational study. Lancet
2001;357:1063–8.
28 Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on
early recurrent ischemic events in acute coronary syndromes: the MIRACL
study: a randomized controlled trial. Myocardial ischemia reduction with
aggressive cholesterol lowering (MIRACL) study investigators. JAMA
2001;285:1711–8.
29 Tonkin AM, Colquhoun D, Emberson J, et al. Of pravastatin in 3260 patients
with unstable angina: results from the LIPID study. Lancet 2000;356:1871–5.
30 Walter DH, Fichtlscherer S, Britten MB, et al. Benefits of immediate initiation of
statin therapy following successful coronary stent implantation in patients with
stable and unstable angina pectoris and Q-wave acute myocardial infarction.
Am J Cardiol 2002;89:1–6.
31 Shiomi M, Ito T, Hirouchi Y, et al. Fibromuscular cap composition is important
for the stability of established atherosclerotic plaques in mature WHHL rabbits
treated with statins. Atherosclerosis 2001;157:75–84.
32 Hunninghake DB. Postdischarge lipid management of coronary artery disease
patients according to the new national cholesterol education program
guidelines. Am J Cardiol 2001;88:37K–41K.
FROM BMJ JOURNALS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Systematic review of interventions to reduce delay in patients with suspected heart
attack
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Objectives: To evaluate the effectiveness of interventions aiming to reduce time from onset
of signs and symptoms of an acute myocardial infarction (AMI) to seeking medical help/
arrival at hospital.
Methods: A systematic review was conducted. Fifteen electronic databases, the internet,
and bibliographies of included studies were searched, and experts in the field of cardiac care
were contacted. Randomised controlled trials (RCTs), controlled trials, and before and after
studies conducted in any setting that assessed an intervention aimed at reducing time from
onset of signs and symptoms of an AMI to seeking medical help and/or arrival in hospital
were eligible for inclusion.
Results: Eleven media/public education intervention studies met the inclusion criteria. Five
(one controlled and four before and after studies) reported the intervention to have a
statistically positive effect on delay time and six (two RCTs and four before and after
studies) reported no statistically significant effect. Three (one RCT and two before and after
studies) of five studies evaluating the effect of the intervention on emergency department
visits reported an increase in this outcome as a result of the intervention, and both studies
(one RCT and one before and after study) examining calls made to emergency switchboards
reported an increase in this outcome after the intervention.
Conclusions: There was little evidence that media/public education interventions reduced
delay. There is some evidence that they may result in an increase in emergency switchboard
calls and emergency department visits. Despite substantial expenditure of time and effort,
methodological deficiencies of the studies mean that it is not possible to make definitive
recommendations.
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